210 Chapter 9 18 kDa translocator protein expression in rodents but not humans. J Cereb Blood Flow Metab. Aug 2017;37(8):2679-2690. doi:10.1177/0271678X17710182 23. Kreisl WC, et al. Comparison of [11C]-(R)-PK 11195 and [11C] PBR28, two radioligands for translocator protein (18 kDa) in human andmonkey: implications for positron emission tomographic imaging of this inflammation biomarker. Neuroimage. 2010;49(4):2924-2932. 24. Datta G, et al. (11)C-PBR28 and (18)F-PBR111 DetectWhiteMatter Inflammatory Heterogeneity in Multiple Sclerosis. J NuclMed. Sep2017;58(9):14771482. doi:10.2967/jnumed.116.187161 25. Banati RB, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain. Nov 2000;123 ( Pt 11)(11):2321-37. doi:10.1093/brain/123.11.2321 26. Cagnin A, et al. In vivo visualization of activated glia by [11C] (R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. Brain. Oct 2001;124(Pt 10):2014-27. doi:10.1093/ brain/124.10.2014 27. Debruyne JC, et al. PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. Eur J Neurol. May 2003;10(3):257-64. doi:10.1046/ j.1468-1331.2003.00571.x 28. Gerhard A, et al. [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology. Sep 9 2003;61(5):686-9. doi:10.1212/01.wnl.0000078192.95645.e6 29. Gerhard A, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis. Feb 2006;21(2):404-12. doi:10.1016/j.nbd.2005.08.002 30. Gerhard A, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. Mov Disord. Jan 2006;21(1):8993. doi:10.1002/mds.20668 31. Gerhard A, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. Mov Disord. Oct 2004;19(10):1221-6. doi:10.1002/mds.20162 32. Ghadery C, et al. Microglial activation in Parkinson’s disease using [(18)F]-FEPPA. J Neuroinflammation. Jan 11 2017;14(1):8. doi:10.1186/s12974-0160778-1 33. Groom GN, et al. PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer’s disease. J Nucl Med. Dec 1995;36(12):2207-10. 34. Henkel K, et al. Imaging of activated microglia with PET and [11C]PK 11195 in corticobasal degeneration. Mov Disord. Jul 2004;19(7):817-821. doi:10.1002/mds.20040 35. Politis M, et al. Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington’s disease gene carriers. Neurobiol Dis. Nov 2015;83:115-21. doi:10.1016/j.nbd.2015.08.011 36. Tai YF, et al. Imaging microglial activation in Huntington’s disease. Brain Res Bull. Apr 30 2007;72(2-3):148-51. doi:10.1016/j. brainresbull.2006.10.029 37. Tomasi G, et al. Novel reference regionmodel reveals increased microglial and reduced vascular binding of 11C-(R)-PK11195 in patients with Alzheimer’s disease. J Nucl Med. Aug 2008;49(8):1249-56. doi:10.2967/jnumed.108.050583 38. Turner MR, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. Apr 2004;15(3):601-9. doi:10.1016/j.nbd.2003.12.012 39. Venneti S, et al. PK11195 labels activated microglia in Alzheimer’s disease and in vivo in a mouse model using PET. Neurobiol Aging. Aug 2009;30(8):121726. doi:10.1016/j.neurobiolaging.2007.11.005 40. Vowinckel E, et al. PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. Journal of Neuroscience Research. Oct 15 1997;50(2):345-353. doi:Doi 10.1002/(Sici)10974547(19971015)50:2<345::Aid-Jnr22>3.0.Co;2-5 41. Yankam Njiwa J, et al. Quantitative longitudinal imaging of activated microglia as a marker of inflammation in the pilocarpine rat model of epilepsy using [(11)C]-( R)-PK11195 PET and MRI. J Cereb Blood Flow Metab. Apr 2017;37(4):12511263. doi:10.1177/0271678X16653615 42. Kuhlmann AC, et al. Cellular and subcellular localization of peripheral benzodiazepine receptors after trimethyltin neurotoxicity. J Neurochem. Apr 2000;74(4):1694-704. doi:10.1046/j.14714159.2000.0741694.x 43. van der Valk P, et al. Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. Neuropathol Appl Neurobiol. Feb 2000;26(1):2-10. doi:10.1046/j.1365-2990.2000.00217.x 44. Versijpt J, et al. Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study. Mult Scler. Apr 2005;11(2):127-34. doi:10.1191/1352458505ms1140oa 45. Oh U, et al. Translocator protein PET imaging for glial activation in multiple sclerosis. J Neuroimmune Pharmacol. Sep 2011;6(3):354-61. doi:10.1007/ s11481-010-9243-6 46. Rissanen E, et al. In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand (1) (1)C-PK11195. J Nucl Med. Jun 2014;55(6):939-44. doi:10.2967/jnumed.113.131698 47. Datta G, et al. Translocator positron-emission tomography and magnetic resonance spectroscopic
RkJQdWJsaXNoZXIy MTk4NDMw